rpe65 genes suffer severe vision problems including night blindness disease progresses people lose functional vision eventually totally blind condition rare affecting 1,000 2,000 people u.s. 10 20 babies born year rpe65 mutated retinal disease spark estimates wall street analysts average forecasting luxturna sales reach $ 364 million 2022 according evaluate drug industry standards anoint blockbuster status products generate $ 1 billion sales luxturna expected modestly successful likely reason spark choosing not price aggressively botching luxturna commercial launch angering insurers providers high price will not serve spark future gene therapies targeting larger commercially lucrative diseases like hemophilia reach market assuming promising